Implantable cardioverter-defibrillators may benefit certain younger patients with mild–moderate heart dysfunction

A new medical study suggests that implantable cardioverter-defibrillators (ICDs) could potentially save lives in younger patients with mild-to-moderate heart dysfunction. Internationally renowned cardiac expert Professor Joseph Selvanayagam presented the findings at the European Society of Cardiology Congress in Munich. The trial, conducted across 18 sites in Australia, Germany, and the United Kingdom, examined whether ICDs, typically used for severe heart conditions, could benefit a group of patients with LVEF 36%--50% and heart muscle scarring.

While the overall trial did not show a significant reduction in sudden cardiac death or serious ventricular arrhythmia, a prespecified analysis revealed benefits in patients under 70 years of age. ICDs function like a personal paramedic, constantly monitoring the heart's rhythm and correcting dangerous irregularities. However, current guidelines limit ICD use to patients with severely reduced heart function.

Selvanayagam's research indicates that in patients with heart scarring and reduced heart function, ICD implantation could potentially reduce sudden cardiac death, offering new treatment options for a broader range of patients.